226 related articles for article (PubMed ID: 36280013)
1. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD.
Torres L; Schuch A; Longo L; Valentini BB; Galvão GS; Luchese E; Pinzon C; Bartels R; Álvares-da-Silva MR
Ann Hepatol; 2023; 28(1):100774. PubMed ID: 36280013
[TBL] [Abstract][Full Text] [Related]
2. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
Liang JX; Ampuero J; Niu H; Imajo K; Noureddin M; Behari J; Lee DH; Ehman RL; Rorsman F; Vessby J; Lacalle JR; Mózes FE; Pavlides M; Anstee QM; Harrison SA; Castell J; Loomba R; Romero-Gómez M;
J Hepatol; 2023 Sep; 79(3):592-604. PubMed ID: 37121437
[TBL] [Abstract][Full Text] [Related]
3. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
4. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Jung J; Loomba RR; Imajo K; Madamba E; Gandhi S; Bettencourt R; Singh S; Hernandez C; Valasek MA; Behling C; Richards L; Fowler K; Sirlin CB; Nakajima A; Loomba R
Gut; 2021 Oct; 70(10):1946-1953. PubMed ID: 33214165
[TBL] [Abstract][Full Text] [Related]
5. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.
Cui J; Ang B; Haufe W; Hernandez C; Verna EC; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2015 Jun; 41(12):1271-80. PubMed ID: 25873207
[TBL] [Abstract][Full Text] [Related]
6. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
Xiao G; Zhu S; Xiao X; Yan L; Yang J; Wu G
Hepatology; 2017 Nov; 66(5):1486-1501. PubMed ID: 28586172
[TBL] [Abstract][Full Text] [Related]
7. A comparison of magnetic resonance elastography (MRE) to biomarker testing for staging fibrosis in non-alcoholic fatty liver disease (NAFLD).
Kaplan JM; Alexis J; Grimaldi G; Islam M; Izard SM; Lee TP
Transl Gastroenterol Hepatol; 2023; 8():7. PubMed ID: 36704653
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
[TBL] [Abstract][Full Text] [Related]
9. A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease.
Mathew JF; Panackel C; Jacob M; Ramesh G; John N
J Clin Exp Hepatol; 2024; 14(5):101407. PubMed ID: 38699513
[TBL] [Abstract][Full Text] [Related]
10. Liver stiffness accuracy by magnetic resonance elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort.
Lara Romero C; Liang JX; Fernández Lizaranzazu I; Ampuero Herrojo J; Castell J; Del Prado Alba C; Domínguez Pascual I; Romero Gómez M
Rev Esp Enferm Dig; 2023 Apr; 115(4):162-167. PubMed ID: 35791792
[TBL] [Abstract][Full Text] [Related]
11. Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.
Tamaki N; Imajo K; Sharpton SR; Jung J; Sutter N; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Kurosaki M; Izumi N; Nakajima A; Loomba R
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):380-387.e3. PubMed ID: 35123096
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
13. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
[TBL] [Abstract][Full Text] [Related]
14. Acoustic radiation force impulse elastography and liver fibrosis risk scores in severe obesity.
da Silva RG; de Miranda MLQ; de Araújo Caldeira Brant PE; Schulz PO; de Fátima Araujo Nascimento M; Schmillevitch J; Vieira A; de Freitas WR; Szutan LA
Arch Endocrinol Metab; 2021 Nov; 65(6):730-738. PubMed ID: 34762779
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Mózes FE; Lee JA; Selvaraj EA; Jayaswal ANA; Trauner M; Boursier J; Fournier C; Staufer K; Stauber RE; Bugianesi E; Younes R; Gaia S; Lupșor-Platon M; Petta S; Shima T; Okanoue T; Mahadeva S; Chan WK; Eddowes PJ; Hirschfield GM; Newsome PN; Wong VW; de Ledinghen V; Fan J; Shen F; Cobbold JF; Sumida Y; Okajima A; Schattenberg JM; Labenz C; Kim W; Lee MS; Wiegand J; Karlas T; Yılmaz Y; Aithal GP; Palaniyappan N; Cassinotto C; Aggarwal S; Garg H; Ooi GJ; Nakajima A; Yoneda M; Ziol M; Barget N; Geier A; Tuthill T; Brosnan MJ; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
Gut; 2022 May; 71(5):1006-1019. PubMed ID: 34001645
[TBL] [Abstract][Full Text] [Related]
16. Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.
Moore JA; Wheless WH; Zhang J; Marsden J; Mauldin PD; Moran WP; Schreiner AD
Dig Dis Sci; 2023 Jul; 68(7):2946-2953. PubMed ID: 37193930
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India.
Prasad M; Gupta S; Kashyap N; Kapil U
Indian J Gastroenterol; 2023 Apr; 42(2):192-198. PubMed ID: 37191918
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
[TBL] [Abstract][Full Text] [Related]
19. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
[TBL] [Abstract][Full Text] [Related]
20. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
